COMPANY

Galectin Therapeutics

HQ: Norcross, GA source · galectintherapeutics.com ↗

Keywords: oncology metabolic metabolic dysfunction-associated steatohepatitis liver cirrhosis fibrosis Colorectal Cancer Hepatic Impairment Prevention of Esophageal Varices NASH - Nonalcoholic Steatohepatitis Nonalcoholic Steatohepatitis Portal Hypertension Psoriasis Cancer of the Bile Duct Gallbladder Cancer Non-Alcoholic Steatohepatitis Lung Cancer Breast Cancer Head and Neck Cancer Prostate Cancer GR-MD-02 GM-CT-01 belapectin

Location: Norcross, GA · source · Oct 15, 2026

Profile checked Oct 10, 2026

10Trials (company is sponsor)

Timeline

Jun 25, 2020 Trial start Phase 2/Phase 3: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis source ↗
Jun 16, 2020 Trial start Phase 1: GT-032 Belapectin Hepatic Impairment source ↗
2015-09 Trial start Phase 2: Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis source ↗
2015-09 Trial start 2: An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis source ↗
2015-06 Trial start Phase 2: Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis source ↗
2013-07 Trial start 1: Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis source ↗
2006-10 Trial start Phase 2: A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer source ↗
2006-09 Trial start Phase 2: Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer source ↗
2005-05 Trial start Phase 2: GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer source ↗
2003-02 Trial start Phase 1: Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors source ↗

Clinical trials (lead sponsor) 10

Record	Title	Phase	Status	Start	Primary completion
NCT04332432	GT-032 Belapectin Hepatic Impairment	Phase 1	Completed	Jun 16, 2020	Mar 9, 2022 (actual)
NCT04365868	Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis	Phase 2/Phase 3	Terminated	Jun 25, 2020	Mar 11, 2025 (actual)
NCT02421094	Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis	Phase 2	Completed	2015-09	Sep 27, 2016 (actual)
NCT02462967	Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis	Phase 2	Completed	2015-06	2017-10 (actual)
NCT02407041	An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis	2	Completed	2015-09	2018-03 (actual)
NCT00388700	A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer	Phase 2	Withdrawn	2006-10	2009-06 (actual)
NCT00386516	Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer	Phase 2	Withdrawn	2006-09	2009-06 (actual)
NCT01899859	Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis	1	Completed	2013-07	2015-02 (actual)
NCT00054977	Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors	Phase 1	Completed	2003-02	2005-04 (actual)
NCT00110721	GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer	Phase 2	Terminated	2005-05	2007-06 (actual)